Table 3.
Protection of vaccinated A/J mice after a T. cruzi challenge
| Immunogen |
Days after challenge live/total animals (% survival)a |
AST ± SD | ||
|---|---|---|---|---|
| 23dpi | 40dpi | 60 dpi | ||
| Mock | 0/15 (0) | 0/15 (0) | 0/15 (0) | 19.3 ± 1.4 |
| YF 17DD | 1/15 (6) | 0/15 (0) | 0/15 (0) | 20.3 ± 1.5 |
| YF17D/E200/Tc | 10/15 (66) | 0/15 (0) | 0/15 (0) | 23.7 ± 2.9** |
| YF17D/NS2B3/Tc | 9/15 (60) | 3/15 (20) | 2/15 (13) | 24.8 ± 5.8*** |
| TEWETGQI/Adjv | 5/6 (83) | 1/6 (16) | 0/6 (0) | 29.7 ± 7.9*** |
a Mice were immunized with medium (Mock), YF 17DD, the two recombinant viruses or with TEWETGQI emulsified in Freund's Adjuvant. Four weeks after the second dose, mice were challenged i.p. with 250 bloodstream trypomastigotes. Average survival times (AST) were significant different (*** P < 0.0005, ** P < 0.001, Mann Whitney test).